Spondyloarthropathies News

Adjusted treatment retention rates after 1 year were lower among patients who switched from etanercept to a biosimilar compared with the historic originator cohort, but nonetheless higher than those who did not switch, according to data published in the Annals of the Rheumatic Diseases.

Pfizer has initiated a global phase 3 study intended to evaluate the safety and therapeutic activity of tofacitinib among adult patients with active ankylosing spondylitis who have had an inadequate response or intolerance to standard treatment with NSAIDs.

CHICAGO — Ixekizumab significantly improved the signs and symptoms of ankylosing spondylitis in patients who previously did not respond to or tolerate TNF inhibitors, according to phase 3 data from the COAST-W trial.

The occurrence rate and disease activity of acute anterior uveitis in ankylosing spondylitis decreased significantly during treatment with golimumab, according to data published in the Journal of Rheumatology.

CHICAGO — Bimekizumab, a monoclonal antibody that neutralizes both IL-17A and IL-17F, significantly improved both musculoskeletal and skin outcomes among patients with active psoriatic arthritis, according to phase 2b data presented at the ACR/ARHP 2018 Annual Meeting.

CHICAGO — Phase 3 data from the MEASURE 3 trial showed that a 300-mg dose of secukinumab sustained improvements in the signs and symptoms of active ankylosing spondylitis over 3 years without increasing the incidence of adverse events compared with a 150-mg dose.

CHICAGO — A newly developed referral strategy for spondyloarthritis had a better balance of sensitivity and specificity than other existing referral strategies, such as ASAS criteria, according to research presented at the ACR/ARHP 2018 Annual Meeting.

CHICAGO — Certolizumab pegol significantly reduced disease activity and signs of inflammation compared with placebo among patients with non-radiographic axial spondyloarthritis, according to 52-week data from the C-axSpAnd trial.

CHICAGO — Statin use, in combination with NSAIDs, significantly reduced disease activity among patients with ankylosing spondylitis, according to data presented at the ACR/ARHP 2018 Annual Meeting.

Researchers found that the most prevalent adverse effect linked to immune checkpoint inhibitors was inflammatory arthritis, and although most patients received long courses of immune suppression, few required checkpoint inhibitor discontinuation, according to data published in Arthritis & Rheumatology.